New study explores how to reverse common blood thinners
NCT ID NCT07312851
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This early-stage study tests a drug called andexanet alfa, which is designed to reverse the effects of common blood thinners like rivaroxaban and apixaban. Researchers will give these blood thinners to 179 healthy volunteers, then give andexanet to see how well it works and how it interacts with another blood thinner, enoxaparin. The goal is to learn more about dosing and timing, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- andexanet alfa
- What this could lead to
- If successful, this could help doctors better understand how to reverse the effects of certain blood thinners in emergencies.
- What could go wrong
- This is a very early Phase 1 study in healthy volunteers, not patients. It only measures lab effects, not real-world outcomes, and may not translate to clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Berlin, 14050, Germany
-
Research Site
Harrow, HA1 3UJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates